Biopharmaceutical company CardioVascular BioTherapeutics, Inc revealed on Tuesday the appointment of Ori Ben-Yehuda, MD, FACC as its new chief medical officer (CMO).

Dr Ben-Yehuda will guide the company's clinical team in current and future development stage research programmes and will be instrumental in leading the clinical research effort for its coronary artery disease and peripheral artery disease programmes, as well as others. He will also assist in transitioning its preclinical programmes to IND stage projects.

Previously, Dr Ben-Yehuda has served as the executive director of the Cardiovascular Research Foundation Clinical Trials Center as well as the deputy editor of Structural Heart: The Journal of the Heart and the Editor-in-Chief of Coronary Artery Disease.

Earlier in his career, Dr Ben-Yehuda was employed as vice president, Cardiovascular Clinical Research at Gilead Sciences, professor of Clinical Medicine at the University of California, San Diego (UCSD) as well as the director of the Coronary Care Unit at UCSD Medical Center.